Interleukin-35(IL-35)is a novel protein comprising IL-12αand IL-27βchains.The IL12A and EBI3 genes are responsible for its production.The study of IL-35 has experienced a substantial increase in interest in recent y...Interleukin-35(IL-35)is a novel protein comprising IL-12αand IL-27βchains.The IL12A and EBI3 genes are responsible for its production.The study of IL-35 has experienced a substantial increase in interest in recent years,as demonstrated by many research papers.Recent clinical studies have shown that individuals who do not have a C-peptide have notably reduced amounts of IL-35 in their blood serum.This is accompanied by a drop in the percentage of IL-35+Treg cells,regulatory B cells,and CD8+FOXP3+cells that produce IL-35.This article em-phasizes the potential significance of IL-35 expression in governing the immune response and its involvement in chronic inflammatory autoimmune diabetes in pancreatic inflammation.It demonstrates IL-35's ability to regulate cytokine proportions,modulate B cells,and protect against autoimmune diabetes.However,further investigation is necessary to ascertain the precise mechanism of IL-35,and meticulous planning is essential for clinical studies.展开更多
The Advanced Glycation End Products(AGE)binding with its receptor can increase reactive oxygen species(ROS)generation through specific signaling mediators.The effect of superoxide(O2-)and O2-mediated ROS and reactive ...The Advanced Glycation End Products(AGE)binding with its receptor can increase reactive oxygen species(ROS)generation through specific signaling mediators.The effect of superoxide(O2-)and O2-mediated ROS and reactive nitrogen species depends on their concentration and location of formation.Nitric oxide(NO)has anti-inflammatory and anticoagulant properties and a vasodilation effect,but NO can be deactivated by reacting with O_(2)^(-).This reaction between NO and O2-produces the potent oxidant ONOO−.Therefore,ONOO-'s regulatory role in AGEs in diabetic cardiovascular complications must considered as a regulator of cardiovascular complications in diabetes.展开更多
Stevia rebaudiana(Bertoni)Bertoni is a plant known for its natural sweeteners and potential health benefits.Traditionally used to treat diabetes,its impact on cellular signaling proteins such as PKC is unknown.This st...Stevia rebaudiana(Bertoni)Bertoni is a plant known for its natural sweeteners and potential health benefits.Traditionally used to treat diabetes,its impact on cellular signaling proteins such as PKC is unknown.This study begins with examining a database to analyse publications related to S.rebaudiana.The objective was to identify its experimentally validated phytochemicals and biological targets and to perform network pharmacological analysis of gene-disease associations.The identified targets are subsequently validated using a mouse model for LPS-induced PKC phosphorylation assay on mouse macrophage cells.The effect of HPTLC-standardized S.rebaudiana extract was also evaluated using FACS,ELISA,and fluorescence microscopical analysis.A total of 32 unique phytochemicals were found to interact with three targeted proteins,including 5′-Adenosine Monophosphate(AMP)-activated protein kinase catalytic subunit alpha-2/beta-1/gamma-1,1,3-beta-D-glucan synthase,and xanthine dehydrogenase/oxidase.Network analysis and molecular modelling also supported tar-geted lead’s binding and inhibition with AMP-activated protein kinase.The LPS significantly enhanced the phosphorylation of PKC in both ex vivo and in vivo assays.The standardised extract,which contains Rebaudioside and Stevioside at 4.82%w/w and 20.12%w/w,respectively,attenuated the phosphorylation of PKC,suppressed nitric oxide(NO)and reactive oxygen species(ROS).This study found that stevia extract inhibited PKC phos-phorylation in macrophages induced by LPS.Additional research is necessary to understand the potential effects of S.rebaudiana in managing PKC-mediated disorders.This includes exploring the mechanisms by which S.rebaudiana may interact with PKC and the possible therapeutic implications for various health conditions associated with PKC dysregulation.展开更多
文摘Interleukin-35(IL-35)is a novel protein comprising IL-12αand IL-27βchains.The IL12A and EBI3 genes are responsible for its production.The study of IL-35 has experienced a substantial increase in interest in recent years,as demonstrated by many research papers.Recent clinical studies have shown that individuals who do not have a C-peptide have notably reduced amounts of IL-35 in their blood serum.This is accompanied by a drop in the percentage of IL-35+Treg cells,regulatory B cells,and CD8+FOXP3+cells that produce IL-35.This article em-phasizes the potential significance of IL-35 expression in governing the immune response and its involvement in chronic inflammatory autoimmune diabetes in pancreatic inflammation.It demonstrates IL-35's ability to regulate cytokine proportions,modulate B cells,and protect against autoimmune diabetes.However,further investigation is necessary to ascertain the precise mechanism of IL-35,and meticulous planning is essential for clinical studies.
文摘The Advanced Glycation End Products(AGE)binding with its receptor can increase reactive oxygen species(ROS)generation through specific signaling mediators.The effect of superoxide(O2-)and O2-mediated ROS and reactive nitrogen species depends on their concentration and location of formation.Nitric oxide(NO)has anti-inflammatory and anticoagulant properties and a vasodilation effect,but NO can be deactivated by reacting with O_(2)^(-).This reaction between NO and O2-produces the potent oxidant ONOO−.Therefore,ONOO-'s regulatory role in AGEs in diabetic cardiovascular complications must considered as a regulator of cardiovascular complications in diabetes.
文摘Stevia rebaudiana(Bertoni)Bertoni is a plant known for its natural sweeteners and potential health benefits.Traditionally used to treat diabetes,its impact on cellular signaling proteins such as PKC is unknown.This study begins with examining a database to analyse publications related to S.rebaudiana.The objective was to identify its experimentally validated phytochemicals and biological targets and to perform network pharmacological analysis of gene-disease associations.The identified targets are subsequently validated using a mouse model for LPS-induced PKC phosphorylation assay on mouse macrophage cells.The effect of HPTLC-standardized S.rebaudiana extract was also evaluated using FACS,ELISA,and fluorescence microscopical analysis.A total of 32 unique phytochemicals were found to interact with three targeted proteins,including 5′-Adenosine Monophosphate(AMP)-activated protein kinase catalytic subunit alpha-2/beta-1/gamma-1,1,3-beta-D-glucan synthase,and xanthine dehydrogenase/oxidase.Network analysis and molecular modelling also supported tar-geted lead’s binding and inhibition with AMP-activated protein kinase.The LPS significantly enhanced the phosphorylation of PKC in both ex vivo and in vivo assays.The standardised extract,which contains Rebaudioside and Stevioside at 4.82%w/w and 20.12%w/w,respectively,attenuated the phosphorylation of PKC,suppressed nitric oxide(NO)and reactive oxygen species(ROS).This study found that stevia extract inhibited PKC phos-phorylation in macrophages induced by LPS.Additional research is necessary to understand the potential effects of S.rebaudiana in managing PKC-mediated disorders.This includes exploring the mechanisms by which S.rebaudiana may interact with PKC and the possible therapeutic implications for various health conditions associated with PKC dysregulation.
